1.95Open2.00Pre Close29 Volume278 Open Interest250.00Strike Price6.34KTurnover393.91%IV-0.08%PremiumJan 17, 2025Expiry Date3.73Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9435Delta0.0496Gamma70.87Leverage Ratio-61.3399Theta0.0000Rho-66.86Eff Leverage0.0007Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet